Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study.

[1]  F. Pasini,et al.  The role of chemotherapy in metastatic gastric cancer. , 2011, Anticancer research.

[2]  J. Ajani,et al.  A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma. , 2011, Future oncology.

[3]  D. Sargent,et al.  Meta-analyses of 22 randomized trials assessing the influence of chemotherapy in advanced/recurrent gastric cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Shah,et al.  Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[5]  J. Ajani,et al.  Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  D. Cunningham,et al.  Capecitabine and oxaliplatin for advanced esophagogastric cancer. , 2010, The New England journal of medicine.

[7]  A. Ohtsu,et al.  Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. , 2009, The Lancet. Oncology.

[8]  Yoon-Koo Kang,et al.  Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  J. Zaluski,et al.  Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  E. Van Cutsem,et al.  Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. , 2008, European journal of cancer.

[11]  J. Ajani,et al.  Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  D. Ilson.  Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Ajani,et al.  Extended safety and efficacy data on S‐1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study , 2007, Cancer.

[14]  J. Ajani,et al.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Haerting,et al.  Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Ajani,et al.  Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Ajani,et al.  Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer : A Report of the V 325 Study Group , 2006 .

[18]  J. Ajani,et al.  Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Mark Rothmann,et al.  Design and analysis of non‐inferiority mortality trials in oncology , 2002, Statistics in medicine.

[20]  R. Martino,et al.  Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. , 2002, The oncologist.

[21]  J. Uchida,et al.  Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats , 1996, Cancer Chemotherapy and Pharmacology.

[22]  M. Fukushima,et al.  Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. , 1996, Anti-cancer drugs.